Meitav Investment House Ltd. Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Meitav Investment House Ltd. reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 37.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,116 shares of the biopharmaceutical company’s stock after selling 23,884 shares during the period. Meitav Investment House Ltd.’s holdings in Halozyme Therapeutics were worth $1,870,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System boosted its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock valued at $1,688,000 after purchasing an additional 200 shares during the last quarter. Verdence Capital Advisors LLC raised its position in shares of Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 252 shares in the last quarter. State of New Jersey Common Pension Fund D increased its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after buying an additional 302 shares during the last quarter. Nations Financial Group Inc. IA ADV raised its holdings in Halozyme Therapeutics by 2.4% in the fourth quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock valued at $672,000 after acquiring an additional 328 shares in the last quarter. Finally, Diversify Advisory Services LLC grew its holdings in Halozyme Therapeutics by 8.5% during the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 418 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $57.77 on Thursday. The firm’s 50 day moving average is $53.07 and its two-hundred day moving average is $54.56. The firm has a market capitalization of $7.35 billion, a P/E ratio of 19.13, a PEG ratio of 0.44 and a beta of 1.25. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 52 week low of $35.50 and a 52 week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 179.82% and a net margin of 41.43%. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Analysts anticipate that Halozyme Therapeutics, Inc. will post 3.87 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. JMP Securities lifted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Finally, HC Wainwright boosted their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.